Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide with DA-EPOCH-R in KSHV-Associated Lymphomas
NCT02228512Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Aug 2014
- Primary completion
- May 2015
- Modality
- Molecular Glues
01
Overview
Phase 2, open-label trial of pomalidomide in primary effusion lymphoma (PEL) and Large B-cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease (HHV8-MCD-LBCL) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 1 year. Planned start Aug 2014; status: withdrawn.
02
Drugs
pomalidomide
03
Conditions
primary effusion lymphoma (PEL)Large B-cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease (HHV8-MCD-LBCL)
Beyond the preview
Go deeper on NCT02228512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228512.